The efficacy of fesoterodine in patients after transurethral resection of the prostate

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Aim. For a long time, benign prostatic hyperplasia (BPH) was considered as only cause of lower urinary tract symptoms (LUTS) in elderly men. More than 30% of patients underwent surgery by the age of 80. Unsatisfactory outcome of surgical treatment of BPH are observed in 9-27% of cases. Various irritative symptoms, which are typical for detrusor overactivity, persist especially often. Currently, anticholinergic drug therapy (m-cholinoblockers) is the main treatment for detrusor overactivity. The aim of our study was to assess the effectiveness of m-cholinoblockers for the treatment of persisted LUTS in men with BPH who had undergone transurethral resection of prostate (TURP). Materials and methods. The study included 60 patients with BPH who underwent TURP. All patients were divided into two groups. In Group 1, anti-inflammatory therapy for 10 days with 1-month follow-up was prescribed. In Group 2, anti-inflammatory therapy was combined with the drug Toviaz® for 1 month. Evaluation of the treatment effectiveness was carried out 3-5 days, 14-15 days and 1 month after TURP, respectively and included voiding diary, IPSS score, QOL, uroflowmetry, adverse events and acute urinary retention. Results. At baseline, in the Group 1 and 2, average urination frequency was 12.6 and 12.7 times per day, the number of urgency episodes was 9.2 and 9.0 times and number of nocturnal voiding episodes was 5,2 and 5.3 times, respectively. The average IPSS score was 19.8 and 19.7 points and Qmax was 6.5 and 6.7 ml/sec, respectively. By the 14th-15th day of therapy, in both groups positive changes were found. There was a significant decrease (p<0.05) in the urination frequency and nocturnal voiding episodes according to voiding diaries, an increase in Qmax and average IPSS and QOL score. The adverse events rate in group 2 was 16.7%. By the 30th day of therapy in the group 1 there were no significant changes. However, in group 2, urination frequency, number of urgency episodes, average IPSS and QOL score decreased to an average of 5.7 times a day, 0.4 times, 1.2 times, 9.3 points and 1.6 points, respectively. Average Qmax increased to 15.5 ml/sec. No adverse events were detected. Conclusion. According to the results of our study, the use of m-cholinoblockers, in particular Fesoterodine (Toviaz®), in combination with standard therapy in patients with detrusor overactivity after TURP is reasonable and allows to effectively and safely alleviate irritative symptoms.

Full Text

Restricted Access

About the authors

A. V Kuz’menko

FGBOU VO «Voronezh State Medical University named after N.N. Burdenko»

MD, associate professor, Head of Department of Urology

V. V Kuz’menko

FGBOU VO «Voronezh State Medical University named after N.N. Burdenko»

MD, professor, professor at the Department of Urology

T. A Gyaurgiev

FGBOU VO «Voronezh State Medical University named after N.N. Burdenko»

Ph.D., associate professor at the Department of Urology


  1. Урология. Российские клинические рекомендации / под ред. Ю.Г. Аляе-ва, П.В. Глыбочко, Д.Ю. Пушкаря. М.: ГЭОТАР-Медиа, 2018. 480 с.
  2. Gratzke C., Bachmann A., Descazeaud A. et al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol. 2015;67(6):1099-1109. Doi: 10.1016/j. eururo.2014.12.038.
  3. Гаджиева З.К., Казилов Ю.Б. Новые возможности лечения комбинированных симптомов нижних мочевыводящих путей у пациентов с доброкачественной гиперплазией предстательной железы - предпосылки и преимущества. Урология. 2017;1:95-102
  4. Krivoborodov G.G., Shkol’nikov M.E., Efremov N.S., Tur E.I., Kravets A.A. Cholinoblockers for treatment of storage symptoms in men with benign prostatic hyperplasia. Effectivnaya farmakoterapiya. 2011;43:26-29. Кривобородов Г.Г., Школьников М.Е., Ефремов Н.С., Тур Е.И., Кравец А.А. Холинолитики в лечении симптомов накопления мочевого пузыря у мужчин с доброкачественной гиперплазией предстательной железы. Эффективная фармакотерапия. 2011;43:26-29.
  5. Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А., Баранников И.И. Хронобиологический статус больных с хроническим простатитом на фоне аденомы простаты. Системный анализ и управление в биомедицинских системах. 2017;16(3):513-316
  6. Кузьменко А.В., Кузьменко В.В., Гяургиев Т.А. Комбинированная медикаментозная терапия больных ДГПЖ. Урология. 2018;1:101-105
  7. Неймарк А.И., Неймарк Б.А., Тор-бик Д.В. Тактика ведения больного доброкачественной гиперплазией предстательной железы при крупном ее объеме. Бюллетень медицинской науки. 2017;1(5):44-53
  8. Винаров А.З., Спивак Л.Г., Миронов А.В. Комбинированная терапия гиперплазии предстательной железы в свете клинических рекомендаций. Урология. 2017;4:120-128
  9. Гаджиева З.К., Аляев Ю.Г., Винаров А.З. Об особенностях выбора медикаментозной терапии при обструктивных заболеваниях нижних мочевыводящих путей. Эффективная фармакотерапия. 2016;41:16-26
  10. Локшин К.Л., Тангриберганов М.Р., Гаджиева З.К. Современные возможности медикаментозной терапии при сохранении ирритативных симптомов после ТУР ДГПЖ. Эффективная фармакотерапия. 2012;39:24-27

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies